0.9785
price down icon4.07%   -0.0415
after-market Handel nachbörslich: .98 0.0015 +0.15%
loading
Schlusskurs vom Vortag:
$1.02
Offen:
$0.98
24-Stunden-Volumen:
149.15K
Relative Volume:
0.05
Marktkapitalisierung:
$7.58M
Einnahmen:
$34.07M
Nettoeinkommen (Verlust:
$-20.13M
KGV:
-0.0572
EPS:
-17.1162
Netto-Cashflow:
$-24.90M
1W Leistung:
-7.69%
1M Leistung:
+25.46%
6M Leistung:
-5.00%
1J Leistung:
-71.22%
1-Tages-Spanne:
Value
$0.9601
$1.055
1-Wochen-Bereich:
Value
$0.9391
$1.14
52-Wochen-Spanne:
Value
$0.61
$3.90

Biofrontera Inc Stock (BFRI) Company Profile

Name
Firmenname
Biofrontera Inc
Name
Telefon
781-245-1325
Name
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Name
Mitarbeiter
85
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-13
Name
Neueste SEC-Einreichungen
Name
BFRI's Discussions on Twitter

Vergleichen Sie BFRI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
BFRI
Biofrontera Inc
0.9785 7.58M 34.07M -20.13M -24.90M -12.92
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
164.84 74.37B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.69 43.81B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.10 41.53B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
22.09 25.03B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
12.52 14.94B 15.05B -883.30M 1.89B -0.74

Biofrontera Inc Aktie (BFRI) Neueste Nachrichten

pulisher
Dec 14, 2024

Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World

Dec 14, 2024
pulisher
Dec 11, 2024

Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 11, 2024
pulisher
Dec 04, 2024

Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg

Dec 04, 2024
pulisher
Dec 03, 2024

Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan

Dec 03, 2024
pulisher
Nov 28, 2024

Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com

Nov 28, 2024
pulisher
Nov 22, 2024

Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz

Nov 22, 2024
pulisher
Nov 22, 2024

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire

Nov 22, 2024
pulisher
Nov 22, 2024

Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks

Nov 22, 2024
pulisher
Nov 22, 2024

Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 21, 2024

Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com

Nov 21, 2024
pulisher
Nov 16, 2024

Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 16, 2024
pulisher
Nov 15, 2024

Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 14, 2024
pulisher
Nov 13, 2024

Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com

Nov 12, 2024
pulisher
Nov 06, 2024

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com

Nov 06, 2024
pulisher
Nov 01, 2024

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire

Oct 31, 2024
pulisher
Oct 29, 2024

Actinic Keratosis Treatment Market Expected to Reach Huge - openPR

Oct 29, 2024
pulisher
Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Oct 23, 2024
pulisher
Oct 15, 2024

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 14, 2024

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Oct 14, 2024
pulisher
Oct 14, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Oct 14, 2024
pulisher
Oct 14, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

Oct 14, 2024
pulisher
Oct 08, 2024

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

Mass. Biotech Receives FDA Approval - Streetwise Reports

Oct 07, 2024
pulisher
Oct 07, 2024

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 04, 2024
pulisher
Oct 04, 2024

Biotech Stocks Facing FDA Decision In October 2024 - RTTNews

Oct 04, 2024
pulisher
Oct 03, 2024

Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com

Oct 03, 2024

Finanzdaten der Biofrontera Inc-Aktie (BFRI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$11.63
price down icon 1.61%
$89.28
price down icon 2.89%
$83.45
price down icon 0.82%
drug_manufacturers_specialty_generic RDY
$15.37
price up icon 1.65%
$135.42
price up icon 0.34%
$12.52
price up icon 3.22%
Kapitalisierung:     |  Volumen (24h):